Literature DB >> 27020557

Trial Watch: Glioblastoma vaccine therapy disappointment in Phase III trial.

Hemi Malkki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27020557     DOI： 10.1038/nrneurol.2016.38

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  16 in total

Review 1.  Advances in immunotherapeutic research for glioma therapy.

Authors:  Jeremy Tetsuo Miyauchi; Stella E Tsirka
Journal:  J Neurol       Date:  2017-12-05       Impact factor: 4.849

Review 2.  EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.

Authors:  Eskil Eskilsson; Gro V Røsland; Gergely Solecki; Qianghu Wang; Patrick N Harter; Grazia Graziani; Roel G W Verhaak; Frank Winkler; Rolf Bjerkvig; Hrvoje Miletic
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

Review 3.  A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.

Authors:  Ahmed Habib; Matthew Pease; Chowdari V Kodavali; Nduka Amankulor; Pascal O Zinn
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

Review 4.  Tumor Vaccines for Malignant Gliomas.

Authors:  Visish M Srinivasan; Sherise D Ferguson; Sungho Lee; Shiao-Pei Weathers; Brittany C Parker Kerrigan; Amy B Heimberger
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 5.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 6.  EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.

Authors:  Manfred Westphal; Cecile L Maire; Katrin Lamszus
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

Review 7.  Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

Authors:  Zhenyi An; Ozlem Aksoy; Tina Zheng; Qi-Wen Fan; William A Weiss
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

8.  MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment.

Authors:  Stefanie Galbán; Wajd N Al-Holou; Hanxiao Wang; Amanda R Welton; Kevin Heist; Xin Kathy Hu; Roeland Gw Verhaak; Yuan Zhu; Carlos Espinoza; Thomas L Chenevert; Ben A Hoff; Craig J Galbán; Brian D Ross
Journal:  Tomography       Date:  2017-03

9.  Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.

Authors:  Kristina Ellwanger; Uwe Reusch; Ivica Fucek; Stefan Knackmuss; Michael Weichel; Thorsten Gantke; Vera Molkenthin; Eugene A Zhukovsky; Michael Tesar; Martin Treder
Journal:  Front Oncol       Date:  2017-05-19       Impact factor: 6.244

10.  Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.

Authors:  Ernest Dodoo; Markus Maeurer; Zhenjiang Liu; Martin Rao; Thomas Poiret; Silvia Nava; Qingda Meng; Anna von Landenberg; Jiri Bartek; Shanshan Xie; Georges Sinclair; Inti Peredo
Journal:  Oncotarget       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.